{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T23:24:11Z","timestamp":1784330651506,"version":"3.55.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Prevention strategies against varicella zoster infection include chemoprophylaxis with acyclovir and live attenuated zoster vaccine. However, resistance to acyclovir has been problematic, and safety concerns have limited the use of the live attenuated vaccine in immunosuppressed patients. Recombinant zoster vaccine, made available in 2017 for the immunocompetent host, has been evaluated for safety, immunogenicity, and efficacy in several immunocompromised settings as well. The present review compares the live attenuated vaccine and the recombinant zoster vaccine and highlights data on the use of recombinant zoster vaccine in different immunocompromised states. Robust data are available for the safety, immunogenicity, and efficacy of the recombinant vaccine in the autologous stem cell population, particularly among patients with multiple myeloma. The vaccine appears safe and immunogenic in populations including those with cancer (solid tumors and hematologic malignancies), HIV-infected patients, and renal transplant recipients. Efficacy and safety data in other populations are awaited before use of the recombinant vaccine can be more widespread. It is anticipated that an increased use of the recombinant zoster vaccine, particularly in immunosuppressed patients, would lead to a decreased use of acyclovir prophylaxis.<\/jats:p>","DOI":"10.1093\/ofid\/ofaa274","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T12:44:32Z","timestamp":1594298672000},"source":"Crossref","is-referenced-by-count":13,"title":["Preventing Varicella-Zoster: Advances With the Recombinant Zoster Vaccine"],"prefix":"10.1093","volume":"7","author":[{"given":"Sahrish","family":"Ilyas","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Wayne State University School of Medicine, Detroit, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranatharthi H","family":"Chandrasekar","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, Wayne State University School of Medicine, Detroit, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,7,9]]},"reference":[{"key":"2020073010170747400_CIT0001","doi-asserted-by":"crossref","DOI":"10.1128\/9781555819156","volume-title":"Clinical Virology Manual","author":"Loeffelholz","year":"2016","edition":"5"},{"key":"2020073010170747400_CIT0002","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJM199607043350107","article-title":"Postherpetic neuralgia\u2014pathogenesis, treatment, and prevention","volume":"335","author":"Kost","year":"1996","journal-title":"N Engl J Med"},{"key":"2020073010170747400_CIT0003","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1056\/NEJMp058091","article-title":"Aging, immunity, and the varicella-zoster virus","volume":"352","author":"Arvin","year":"2005","journal-title":"N Engl J Med"},{"key":"2020073010170747400_CIT0004","volume-title":"Diagnostic Microbiology of the Immunocompromised Host","author":"Randall","year":"2016","edition":"2"},{"key":"2020073010170747400_CIT0005","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00007890-198001000-00010","article-title":"Varicella-zoster virus infection after marrow transplantation for aplastic anemia or leukemia","volume":"29","author":"Atkinson","year":"1980","journal-title":"Transplantation"},{"key":"2020073010170747400_CIT0006","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1093\/infdis\/152.6.1172","article-title":"Infection with varicella-zoster virus after marrow transplantation","volume":"152","author":"Locksley","year":"1985","journal-title":"J Infect Dis"},{"key":"2020073010170747400_CIT0007","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/infdis\/153.5.840","article-title":"Clinical and subclinical reactivations of varicella-zoster virus in immunocompromised patients","volume":"153","author":"Ljungman","year":"1986","journal-title":"J Infect Dis"},{"key":"2020073010170747400_CIT0008","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1083-8791(00)70051-6","article-title":"Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome","volume":"6","author":"Koc","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020073010170747400_CIT0009","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/sj.bmt.1702190","article-title":"Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir","volume":"25","author":"Steer","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"2020073010170747400_CIT0010","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/1097-0142(19920201)69:3<784::AID-CNCR2820690328>3.0.CO;2-M","article-title":"Long-term sequelae of autologous bone marrow or peripheral stem cell transplantation for lymphoid malignancies","volume":"69","author":"Vose","year":"1992","journal-title":"Cancer"},{"key":"2020073010170747400_CIT0011","first-page":"1254","article-title":"Herpes zoster in systemic lupus erythematosus","volume":"22","author":"Manzi","year":"1995","journal-title":"J Rheumatol"},{"key":"2020073010170747400_CIT0012","first-page":"84","article-title":"Herpes zoster infections in systemic lupus erythematosus: risk factors and outcome","volume":"21","author":"Kahl","year":"1994","journal-title":"J Rheumatol"},{"key":"2020073010170747400_CIT0013","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/infdis\/166.5.1153","article-title":"Herpes zoster and human immunodeficiency virus infection","volume":"166","author":"Buchbinder","year":"1992","journal-title":"J Infect Dis"},{"key":"2020073010170747400_CIT0014","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1097\/00002030-199510000-00006","article-title":"Herpes zoster, immunological deterioration and disease progression in HIV-1 infection","volume":"9","author":"Veenstra","year":"1995","journal-title":"AIDS"},{"key":"2020073010170747400_CIT0015","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020073010170747400_CIT0016","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1128\/AAC.00615-10","article-title":"Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management","volume":"55","author":"Piret","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2020073010170747400_CIT0017","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1001\/archinte.163.1.76","article-title":"Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics","volume":"163","author":"Reyes","year":"2003","journal-title":"Arch Intern Med"},{"key":"2020073010170747400_CIT0018","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1086\/378416","article-title":"Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects","volume":"188","author":"DeJesus","year":"2003","journal-title":"J Infect Dis"},{"key":"2020073010170747400_CIT0019","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1128\/JCM.42.1.242-249.2004","article-title":"Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up","volume":"42","author":"Danve-Szatanek","year":"2004","journal-title":"J Clin Microbiol"},{"key":"2020073010170747400_CIT0020","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/cid\/cis879","article-title":"Persistence and antiviral resistance of varicella zoster virus in hematological patients","volume":"56","author":"van der Beek","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2020073010170747400_CIT0021","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1159\/000167987","article-title":"Foscarnet nephrotoxicity: mechanism, incidence and prevention","volume":"9","author":"Deray","year":"1989","journal-title":"Am J Nephrol"},{"key":"2020073010170747400_CIT0022","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.clinthera.2018.07.006","article-title":"Antiviral therapies for herpesviruses: current agents and new directions","volume":"40","author":"Poole","year":"2018","journal-title":"Clin Ther"},{"key":"2020073010170747400_CIT0023","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/jac\/dkq198","article-title":"ASP2151, a novel helicase\u2013primase inhibitor, possesses antiviral activity against varicella\u2013zoster virus and herpes simplex virus types 1 and 2","volume":"65","author":"Chono","year":"2010","journal-title":"J Antimicrob Chemo"},{"key":"2020073010170747400_CIT0024","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/1346-8138.13948","article-title":"Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: a randomized, double-blind, valaciclovir-controlled phase 3 study","volume":"44","author":"Kawashima","year":"2017","journal-title":"J Dermatol"},{"key":"2020073010170747400_CIT0025","first-page":"1","article-title":"Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"2020073010170747400_CIT0026","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"2020073010170747400_CIT0027","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/cid\/ciw854","article-title":"Effectiveness and duration of protection provided by the live-attenuated herpes zoster vaccine in the Medicare population ages 65 years and older","volume":"64","author":"Izurieta","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2020073010170747400_CIT0028","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/infdis\/jiw047","article-title":"Declining effectiveness of herpes zoster vaccine in adults aged \u226560 years","volume":"213","author":"Tseng","year":"2016","journal-title":"J Infect Dis"},{"key":"2020073010170747400_CIT0029","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/cid\/cis638","article-title":"Persistence of the efficacy of zoster vaccine in the Shingles Prevention Study and the Short-Term Persistence Substudy","volume":"55","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2020073010170747400_CIT0030","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/cid\/ciu918","article-title":"Long-term persistence of zoster vaccine efficacy","volume":"60","author":"Morrison","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020073010170747400_CIT0031","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"2020073010170747400_CIT0032","doi-asserted-by":"crossref","first-page":"103","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020073010170747400_CIT0033","doi-asserted-by":"crossref","first-page":"91","DOI":"10.15585\/mmwr.mm6804a4","article-title":"Postlicensure safety surveillance of recombinant zoster vaccine (Shingrix)\u2014United States, October 2017-June 2018","volume":"68","author":"Hesse","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020073010170747400_CIT0034","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","article-title":"Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older","volume":"375","author":"Cunningham","year":"2016","journal-title":"N Engl J Med"},{"key":"2020073010170747400_CIT0035","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/infdis\/jiy382","article-title":"Herpes zoster vaccines","volume":"218","author":"Cunningham","year":"2018","journal-title":"J Infect Dis"},{"key":"2020073010170747400_CIT0036","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1093\/cid\/ciz770","article-title":"Adjuvanted recombinant glycoprotein E herpes zoster vaccine","volume":"70","author":"Levin","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2020073010170747400_CIT0037","article-title":"The adjuvanted recombinant zoster vaccine in adults aged \u226565 years previously vaccinated with a live-attenuated herpes zoster vaccine","author":"Dagnew","year":"","journal-title":"J Infect Dis"},{"key":"2020073010170747400_CIT0038","doi-asserted-by":"crossref","first-page":"S414","DOI":"10.1093\/ofid\/ofx163.1038","article-title":"Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine in older adults previously vaccinated with a live-attenuated herpes zoster vaccine: a phase III, group-matched, clinical trial","volume":"4(Suppl 1)","author":"Grupping","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2020073010170747400_CIT0039","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/j.bbmt.2019.07.036","article-title":"Recombinant zoster vaccine significantly reduces the impact on quality of life caused by herpes zoster in adult autologous hematopoietic stem cell transplant recipients: a randomized placebo-controlled trial (ZOE-HSCT)","volume":"25","author":"Curran","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020073010170747400_CIT0040","doi-asserted-by":"crossref","first-page":"380","DOI":"10.7326\/M18-2347","article-title":"A cost-effectiveness analysis of vaccination for prevention of herpes zoster and related complications: input for national recommendations","volume":"170","author":"Prosser","year":"2019","journal-title":"Ann Intern Med"},{"key":"2020073010170747400_CIT0041","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/S0140-6736(18)30631-7","article-title":"Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Winston","year":"2018","journal-title":"Lancet"},{"key":"2020073010170747400_CIT0042","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1182\/blood-2014-04-573048","article-title":"A phase 1\/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients","volume":"124","author":"Stadtmauer","year":"2014","journal-title":"Blood"},{"key":"2020073010170747400_CIT0043","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jama.2019.9053","article-title":"Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation. A randomized clinical trial","volume":"322","author":"Batista","year":"2019","journal-title":"JAMA"},{"key":"2020073010170747400_CIT0044","first-page":"S417","article-title":"Immunogenicity and safety of a candidate subunit adjuvanted herpes zoster vaccine in adults with solid tumors vaccinated before or during immunosuppressive chemotherapy treatment: a phase II\/III, randomized clinical trial","volume":"4","author":"Vink","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2020073010170747400_CIT0045","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/infdis\/jiu606","article-title":"Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1\/2a randomized, placebo-controlled study","volume":"211","author":"Berkowitz","year":"2015","journal-title":"J Infect Dis"},{"key":"2020073010170747400_CIT0046","first-page":"181","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase 3, randomized clinical trial","volume":"70","author":"Vink","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2020073010170747400_CIT0047","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis","volume":"19","author":"Dagnew","year":"2019","journal-title":"Lancet Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaa274\/33478355\/ofaa274.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/7\/ofaa274\/33550380\/ofaa274.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/7\/ofaa274\/33550380\/ofaa274.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T19:14:51Z","timestamp":1696360491000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaa274\/5869344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,1]]},"references-count":47,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaa274","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,7]]},"published":{"date-parts":[[2020,7,1]]},"article-number":"ofaa274"}}